Refine by
Diabetes Patient Articles & Analysis
46 articles found
A New Drug to Reduce Heart Attacks and Strokes The newly approved drug Sotagliflozin (Inpefa) has shown promise in reducing heart attacks and strokes among patients with type 2 diabetes and chronic kidney disease. It works as a dual SGLT1 and SGLT2 inhibitor, helping to regulate blood sugar levels while also protecting the heart. Clinical trials demonstrated a ...
In certain disease states, especially in patients with diabetes, the production of glycated collagen increases due to elevated blood glucose levels. ...
By encapsulating drugs within these microspheres, pharmaceutical companies are able to improve patient compliance, reduce dosing frequency, and enhance therapeutic outcomes. ...
Diabetes, specifically Type 1 and Type 2 Diabetes Mellitus, remains one of the most commonly encountered metabolic diseases worldwide. ...
AMPK can stop the metabolism of rapid tumor proliferation as well as restore the normal function of liver and other tissues in diabetic patients is a hot topic in disease research. AMPK and viral infections The pharmacological activity of AMPK plays an important role in the accumulation of lipids in the cells and in the self-replication of the virus. ...
In China, there are more than 114 million adults with diabetes, accounting for about a quarter of the world's diabetes patients. ...
Early clinical trial results suggest that low-dose IL-2 treatment has a certain safety and efficacy in terms of disease attacks in autoimmune patients [5]. Beta LifeScience provides IL-2 and its receptor proteins of different species and tags, which helps the development of IL-2 drugs and cell therapy drugs. ...
Produced using bioreactors, biopharmaceuticals include vaccines, therapeutic proteins, blood and blood components, and tissues.4 Due to their absence of chemicals, biopharmaceuticals have seen a surge in demand and acceptance in recent years.4Could Bioreactors Provide a Cure for Diabetes?Diabetes is a disease caused by the pancreas not producing enough insulin, ...
Metformin is a classic first-line hypoglycemic agent for patients with type 2 diabetes, and is an essential drug in combination regimenes. ...
According to a study by Health Wealth Safe, remote patient monitoring programs for diabetes management can improve glucose control and reduce hospitalization rates by up to 50%. ...
Patients with HFpEF, for example, are more likely to be older, with a two-fold predominance of females. ...
Most patients with HFpEF also display normal LV volumes and an abnormal diastolic filling pattern (i.e, diastolic dysfunction). ...
Our sublingual “insulin+” product will be positioned in a particular segment of this market : it will be prescribed for type II diabetes patients, who do not respond sufficiently to GLP-1 analogues alone. ...
HFpEF is a complex disease which accounts for more than half of all heart failure (HF) hospital admissions and is an increasing disease burden. [1] The prevalence of HFpEF is climbing, reflecting an increasingly elderly and comorbid population, as well as reinforcing the need for more effective therapies.[2] SGLT2is are a class of anti-diabetic drugs that have demonstrated large ...
Healthcare professionals performed the evaluation with 158 patients either with or without diabetes. Fresh capillary whole blood was tested using the Embrace system. ...
LFQ is frequently used to search tumor biomarkers in clinical studies, as tumor adjacent or normal tissues are often treated as control group. de Oliveira et al. found that MMP-7 was presented as a more promising biomarker associated with useful assays of clinical practice for gastric adenocarcinoma patient diagnosis via LFQ results. Urine E-cadherin was supposed to be a marker ...
Good decision-making relies on good information. That’s why data collection is so important to businesses of all types. In healthcare, it can literally be a life-and-death concern. Currently, two data-related trends are delivering new levels of optimization in hospitals with the potential to vastly improve operations and safety: The convergence of information technology (IT) systems ...
The total number of diabetes patients in China will continue to increase in the next 20 years, and is expected to reach 175 million by 2045. Having diabetes in such a large number of people is a huge health hazard. At the moment when the novel coronavirus is raging around the world, the mortality rate of the novel coronavirus pneumonia in ...
The median claims cost for test strips was $325.54 per person per year. The low-value care worsens patient-centered outcomes and imparts a negative economic effect. Thus, one should avoid routine multiple daily self-glucose monitoring in adults with stable type 2 diabetes or on agents that do not cause hypoglycemia. ...
A patient’s reaction is normally, “Oh my god…. ...